Sign up
Pharma Capital

Amryt Pharma signs exclusive distributor agreement in Switzerland

The tie-up is with RCC Pharma, a leading Swiss pharmaceutical company with expertise in early access programmess in rare and orphan diseases
Amryt acquired the exclusive marketing rights for Lojuxta in the EU, Switzerland, Middle East, North Africa, Turkey and Israel in December 2016

Amyrt Pharmaceuticals PLC (LON:AMYT) has inked an exclusive distributor agreement for Lojuxta in Switzerland.

The tie-up is with RCC Pharma, a leading Swiss pharmaceutical company with expertise in early access programmes in rare and orphan diseases.

READ: Amryt Pharma inks exclusive Saudi Arabian distribution agreement for its Lojuxta and AP101 drugs

Lojuxta treats a rare and life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.

Amryt estimates there are around 15 patients in Switzerland with HoFH.

The company has previously received requests from clinicians for access to Lojuxta from Swiss patients and the agreement means it will now be able to more effectively respond to such requests.

This latest distribution deal follows on from the agreement which covers Amryt’s products in Saudi Arabia, announced back in November.

Working on more partnerships

“This new distribution agreement with RCC marks another key step as we expand our footprint for Lojuxta across Europe, the Middle East, and North Africa,” said chief executive Joe Wiley.

“RCC is a leading Swiss company with particular expertise in rare diseases, and this agreement will help us to bring Lojuxta to patients suffering from HoFH in Switzerland.”

READ: Amryt Pharma raising €15mln to fund development of breakthrough skin treatment

He added: “We continue to work on further partnerships across our licensed territories for Lojuxta, and look forward to announcing further developments.”

View full AMYT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.